Poly(ADP-Ribose) Polymerase Inhibitors [MoA]

Known as: Poly ADP Ribose Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase Inhibitors, Poly ADP-Ribose Polymerase Inhibitors 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
024620102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD… (More)
Is this relevant?
2017
2017
Breast cancer is the most common cancer in women worldwide. Treatment is chosen according to its hormone receptor status and… (More)
Is this relevant?
2017
2017
The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth… (More)
  • table 1
Is this relevant?
2016
2016
 
Is this relevant?
Review
2016
Review
2016
UNLABELLED : High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Review
2016
Review
2016
Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-repair pathways. The proteins encoded by… (More)
  • table I
  • table II
  • table III
Is this relevant?
Review
2015
Review
2015
INTRODUCTION The significant challenge posed by cancer to human healthcare has led to the exploration of new approaches to combat… (More)
Is this relevant?
2014
2014
Platinum drugs and PARP inhibitors ("PARPis") are considered to be effective in BRCA-associated cancers with impaired DNA repair… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • table 2
Is this relevant?
2014
2014
The heterogeneous delivery of drugs in tumors is an established process contributing to variability in treatment outcome. Despite… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?